GlassScriptPhysician profile
Diondra Johnson
NPI 1417557737
$1,093.90
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $314 · 2023: $453 · 2024: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $141.26 | 2023-2024 | Mounjaro, Jardiance, Emgality |
| Forte Bio-Pharma LLC | $105.75 | 2022-2023 | |
| Abbvie INC. | $73.55 | 2023-2024 | |
| Protega Pharmaceutials INC | $73.03 | 2022 | |
| Nevro Corp. | $69.69 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.73 | 2022-2024 | Xifaxan, Trulance |
| Boston Scientific Corporation | $52.27 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.11 | 2023-2024 | Jardiance |
| Abbott Laboratories | $50.16 | 2023-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $48.36 | 2023-2024 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $46.76 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $41.36 | 2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $30.04 | 2023-2024 | Airsupra, Farxiga |
| Inari Medical, INC. | $28.24 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Ultragenyx Pharmaceutical INC. | $27.02 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $24.56 | 2024 | Otezla, Repatha |
| Alnylam Pharmaceuticals INC. | $22.36 | 2023 | Onpattro |
| Scilex Pharmaceuticals INC. | $21.00 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.98 | 2024 | Voquezna |
| Medtronic, INC. | $18.82 | 2024 | Intellis Adaptivestim |
| Daiichi Sankyo INC. | $18.14 | 2024 | Injectafer |
| Edwards Lifesciences Corporation | $17.90 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Pfizer INC. | $15.41 | 2023 | |
| Glaxosmithkline, LLC. | $15.36 | 2024 | Shingrix, Arexvy |
| Hikma Pharmaceuticals USA | $13.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diondra Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.